Industry News

Rigel Pharmaceuticals today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to each employee's employment with Rigel, in accordance with NASDAQ Listing Rule 5635 (c). Specifically, Rigel granted 300,000 stock options to Eldon C. Mayer III, Rigel's newly appointed EVP,..."/>
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
VCA Inc., a leading animal healthcare company in the United States and Canada, will present at the 25th Annual Credit Suisse Healthcare Conference on Monday, November 7 th, at The Phoenician in Scottsdale, Arizona. The VCA Inc. presentation is scheduled to begin at 8:00 am MST.. VCA Inc. will make a presentation on the company, including recent operating results."/>
VCA Inc. to Present at 25th Annual Credit Suisse Healthcare Conference
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Tuesday, October 11, 2016, prior to the market open, it will report the results of its Phase IIb dose-ranging clinical trial of SPN-812 in children for the treatment of attention deficit hyperactivity disorder.. Supernus will hold a conference call with..."/>
Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with ADHD
Diplomat Pharmacy, Inc. is celebrating American Pharmacists Month with a campaign to honor pharmacists in specialty and explore the myths, facts, and possibilities of what a pharmacist in specialty can do for you. Diplomat released a series of videos in which children are asked about the world of pharmacy. Watch the videos at"/>
Diplomat Celebrates American Pharmacists Month With National Campaign
Integer Holdings Corporation, a leading medical device outsource manufacturer, today announced that Jeremy Friedman has been named Executive Vice President and Chief Operating Officer. In this newly established role, Mr. Friedman will have responsibility for the Company's Advanced Surgical& Orthopedic, Cardio& Vascular and Cardiac Rhythm Management& Neuromodulation product categories as well as the Supply Chain, Lean Enterprise, and Enterprise..."/>
Integer Names Jeremy Friedman Chief Operating Officer
Cross Country Healthcare, Inc. will hold its quarterly conference call to discuss its third quarter 2016 financial results on Thursday, November 3, 2016 at 9:00 a.m. Eastern Time. Cross Country Healthcare, Inc. intends to distribute its earnings press release after the close of business on Wednesday, November 2, 2016.. This call will be webcast live and can be accessed at the Company’ s website at or by dialing 800-857-6331..."/>
Cross Country Healthcare Announces Third Quarter 2016 Earnings Release Date and Conference Call Information
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide an update on the Keyzilen TM development program tomorrow, Tuesday, October 11, 2016. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time to discuss the program update for Keyzilen..."/>
Auris Medical to Announce Keyzilen Program Update and Host Conference Call and Webcast Tomorrow, October 11, 2016
Illumina, Inc. today announced estimated third quarter revenue of approximately $607 million, a 10% increase compared to $550 million in the third quarter of 2015. This unaudited estimate, based on management's preliminary financial analysis, is lower than the third quarter revenue guidance of $625 million to $630 million. The shortfall in quarterly revenue was driven by a larger than anticipated year-over-year decline in high throughput sequencing instruments."/>
Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2016
Ocera Therapeutics, Inc., a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming 2016 BIO Investor Forum being held October 18-19, 2016 at the Westin St. Francis Hotel in San Francisco, California. Ocera’ s presentation will take place in the Elizabethan B Room at 8:30 AM Pacific Time.."/>
Ocera to Present at the 2016 BIO Investor Forum
CONMED Corporation today announced that it will report financial results for the third quarter of fiscal year 2016 after the market close on Thursday, October 27, 2016. The Company’ s management will host a conference call at 5:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 844-889-7792 or 661-378-9936 and enter the passcode 95238932.."/>
CONMED Corporation to Announce Third Quarter 2016 Financial Results on October 27, 2016
Sophiris Bio Inc., a biopharmaceutical company developing topsalysin for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 2016 BIO Investor Forum. The presentation is scheduled for Tuesday, October 18, 2016 at 10:30 a.m. PDT in San Francisco. The presentation will be webcast live and can be accessed..."/>
Sophiris Bio to Present at the 2016 BIO Investor Forum
PRA Health Sciences, Inc. will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will also host a conference call on Thursday, November 3 at 9:00 a.m. to discuss the results with members of the investment community.. To participate via telephone, investors and analysts should dial 930-8062 within the United States or 336-7647 outside the United States approximately 10 minutes prior to the call start time."/>
PRA Health Sciences to Report Third Quarter 2016 Earnings
Elbit Imaging Ltd. announced today that it was informed by Gamida Cell Ltd., an indirect associate of the Company, that U.S. Food and Drug Administration has granted Breakthrough Therapy Designation status to Gamida's NiCord ®, due to improvement in absorption of neutrophils blood cells in bone marrow transplant for patients with high risk hematological malignancies.. Breakthrough therapy designation is granted to a drug that is intended to..."/>
Elbit Imaging Ltd. Announces That Gamida Cell Has Received FDA Breakthrough Therapy Designation for Nicord
Agilent Technologies Inc. will showcase its latest innovations at analytica China 2016, the leading Chinese exhibition for laboratory technology, analysis, biotechnology and diagnostics, in Shanghai, Oct. 10-12, 2016. These innovations are industry-leading and are designed to meet the specific needs of the markets Agilent serves, including China. "We innovate with a purpose-our solutions are designed to improve the science and the economics of the..."/>
Agilent Technologies Showcases Innovative Laboratory Solutions at analytica China 2016
NeuroMetrix, Inc. reported today that it has been selected to showcase Quell ® Wearable Pain Relief Technology™ at the Discover Blue: New York City event hosted by the Bluetooth Special Interest Group on October 12 th. "We’ re excited that Quell was selected to participate in the Discover Blue Event,” said Frank McGillin, Senior Vice President and General Manager, Consumer, of NeuroMetrix.“ Connected devices are creating new possibilities in healthcare and Quell is a..."/>
NeuroMetrix Announces Participation in Discover Blue: New York City Bluetooth Event
Ossur Hf : Transactions in relation to share buyback program
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the third quarter ended September 30, 2016 on Thursday, October 27, 2016 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio webcast on Thursday, October 27, 2016, at 10:00 a.m. Eastern Time. To participate in this conference call, dial 888-487-0355 or..."/>
Alexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday, October 27, 2016
PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, today announced that it has advanced into a new and promising phase of research at the University of Northern Colorado in its quest to develop targeted cannabinoid-based chemotherapy utilizing the Cell-in-a-Box ® technology."/>
PharmaCyte Biotech Cannabinoid Research Shows Promise for Success

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology643 Articles
Consumer Discretionary571 Articles
Financials487 Articles
Industrials345 Articles
Health Care313 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at